Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 3253 | 285.07 |
09:34 ET | 1899 | 285.205 |
09:36 ET | 300 | 285.6275 |
09:38 ET | 1900 | 283.79 |
09:39 ET | 100 | 284.255 |
09:45 ET | 500 | 284.29 |
09:48 ET | 107 | 283.915 |
09:54 ET | 950 | 284.18 |
09:56 ET | 4314 | 285.0125 |
09:57 ET | 800 | 283.19 |
09:59 ET | 2100 | 283.2 |
10:01 ET | 1000 | 282.6525 |
10:03 ET | 849 | 284 |
10:06 ET | 1981 | 283.5 |
10:08 ET | 1529 | 283.75 |
10:10 ET | 400 | 284.02 |
10:12 ET | 161 | 283.78 |
10:14 ET | 714 | 283.605 |
10:17 ET | 600 | 283.89 |
10:24 ET | 5752 | 283.76 |
10:26 ET | 2941 | 283.49 |
10:28 ET | 200 | 283.33 |
10:30 ET | 200 | 282.62 |
10:32 ET | 400 | 282.325 |
10:33 ET | 200 | 282.39 |
10:35 ET | 600 | 282.07 |
10:39 ET | 500 | 283.45 |
10:42 ET | 244 | 281.67 |
10:46 ET | 400 | 282.59 |
10:48 ET | 200 | 282.815 |
10:51 ET | 100 | 283.605 |
10:57 ET | 400 | 283.01 |
11:02 ET | 100 | 283.25 |
11:04 ET | 100 | 283.23 |
11:06 ET | 358 | 283.21 |
11:08 ET | 210 | 283.295 |
11:11 ET | 300 | 282.57 |
11:13 ET | 762 | 281.42 |
11:15 ET | 1400 | 281.27 |
11:18 ET | 124 | 281.865 |
11:22 ET | 757 | 282.525 |
11:24 ET | 170 | 283.81 |
11:26 ET | 152 | 283.075 |
11:27 ET | 300 | 283.025 |
11:29 ET | 1699 | 282.745 |
11:31 ET | 691 | 282.935 |
11:33 ET | 630 | 283.62 |
11:38 ET | 619 | 283.47 |
11:40 ET | 835 | 283.6 |
11:42 ET | 4354 | 284.07 |
11:44 ET | 300 | 282.895 |
11:45 ET | 100 | 283.33 |
11:51 ET | 300 | 282.72 |
11:54 ET | 100 | 282.4 |
12:00 ET | 100 | 282.31 |
12:03 ET | 300 | 281.13 |
12:05 ET | 300 | 280.49 |
12:07 ET | 100 | 279.57 |
12:14 ET | 100 | 278.8 |
12:18 ET | 408 | 278 |
12:20 ET | 505 | 278.4816 |
12:21 ET | 200 | 279.18 |
12:23 ET | 477 | 279.885 |
12:25 ET | 100 | 279.9073 |
12:27 ET | 500 | 280.435 |
12:30 ET | 500 | 281.98 |
12:32 ET | 100 | 281.88 |
12:34 ET | 100 | 281.99 |
12:36 ET | 1280 | 281.23 |
12:39 ET | 1400 | 281.63 |
12:41 ET | 400 | 281.095 |
12:45 ET | 200 | 281.13 |
12:48 ET | 300 | 280.97 |
12:50 ET | 128 | 281.395 |
12:52 ET | 100 | 281.14 |
12:54 ET | 100 | 280.98 |
12:57 ET | 100 | 281.44 |
12:59 ET | 300 | 281.08 |
01:01 ET | 100 | 281.53 |
01:06 ET | 4000 | 279.82 |
01:08 ET | 300 | 280.275 |
01:10 ET | 300 | 280.28 |
01:15 ET | 2140 | 279.55 |
01:17 ET | 480 | 279.52 |
01:19 ET | 200 | 279.745 |
01:21 ET | 1207 | 279.715 |
01:24 ET | 700 | 279.5 |
01:26 ET | 100 | 279.5 |
01:30 ET | 500 | 279.49 |
01:33 ET | 100 | 279.465 |
01:35 ET | 800 | 279.31 |
01:37 ET | 100 | 279.3 |
01:39 ET | 100 | 280.1 |
01:42 ET | 730 | 280.54 |
01:51 ET | 400 | 280.29 |
01:55 ET | 400 | 280.005 |
01:57 ET | 100 | 280.13 |
02:00 ET | 506 | 279.8 |
02:04 ET | 100 | 279.445 |
02:06 ET | 200 | 279.54 |
02:09 ET | 100 | 279.895 |
02:15 ET | 350 | 280.205 |
02:18 ET | 100 | 280.53 |
02:22 ET | 185 | 280.78 |
02:24 ET | 100 | 281.14 |
02:29 ET | 100 | 281.14 |
02:33 ET | 100 | 281.065 |
02:38 ET | 100 | 281.15 |
02:40 ET | 200 | 281.25 |
02:45 ET | 119 | 281.415 |
02:49 ET | 300 | 281.06 |
02:56 ET | 100 | 281.135 |
02:58 ET | 600 | 281.285 |
03:02 ET | 100 | 281.22 |
03:03 ET | 628 | 281.15 |
03:05 ET | 100 | 281.285 |
03:07 ET | 100 | 281.325 |
03:09 ET | 200 | 281.645 |
03:14 ET | 400 | 281.555 |
03:16 ET | 670 | 281.31 |
03:18 ET | 100 | 281.06 |
03:23 ET | 110 | 281.06 |
03:27 ET | 300 | 281.72 |
03:30 ET | 100 | 281.67 |
03:32 ET | 710 | 281.36 |
03:34 ET | 2520 | 279.725 |
03:38 ET | 100 | 279.74 |
03:41 ET | 499 | 279.235 |
03:43 ET | 500 | 278.88 |
03:45 ET | 300 | 278.5128 |
03:48 ET | 147 | 278.5124 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.9B | -12.1x | --- |
Cytokinetics Inc | 6.0B | -9.9x | --- |
Summit Therapeutics Inc | 5.5B | -46.9x | --- |
Revolution Medicines Inc | 6.3B | -10.2x | --- |
Viking Therapeutics Inc | 5.2B | -57.3x | --- |
Nuvalent Inc | 5.1B | -31.1x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.42 |
EPS | $-23.08 |
Book Value | $20.39 |
P/E Ratio | -12.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.